摘要
目的探讨布地奈德鼻喷对变应性鼻炎-哮喘综合征(CARAS)的疗效及对呼出气一氧化氮(FENO)和血清炎性因子的影响。方法随机将2017年10月~2018年10月在医院确诊的CARAS患者106例分为治疗组和对照组,每组53例。对照组口服给予抗白三烯、抗组胺治疗,并经气管吸入药物抗炎、舒张支气管治疗,治疗组在对照组基础上加用布地奈德鼻喷治疗,分析两组的临床有效率、疾病复发率,以及治疗前后呼出气一氧化氮(FENO)、痰嗜酸性粒细胞(EOS)以及血清免疫球蛋白E(IgE)、白细胞介素-5(IL-5)的变化。结果治疗3月后,治疗组有效率(92.45%)明显高于对照组(75.47%)(P<0.05);停药和药物减量后,半年内疾病总复发率(26.41%)明显低于对照组(47.16%)(P<0.05);治疗组FENO及EOS、IgE、IL-5水平下降较对照组明显(P<0.05)。结论对CARAS患者的治疗需控制鼻部炎症,在常规哮喘治疗方案基础上联合布地奈德鼻喷,能明显降低炎性因子和复发率,改善疾病预后,值得临床推广借鉴。
Objective To explore the efficacy of budesonide nasal spray in treatment of combined allergic rhinitis and asthma syndrome(CARAS)and its effect on fractional exhaled nitric oxide(FENO)and serum inflammatory cytokines.Methods A total of 106 patients who were diagnosed with CARAS in our hospital from October 2017 to October 2018 were randomly divided into a treatment group and a control group,with 53 patients for each group.Both the control group and the treatment group were orally administered with antileukotriene and antihistamine and inhaled anti-inflammatory drugs and bronchodilator through the trachea.In addition,the treatment group received budesonide nasal spray.Analysis was made for the two group in terms of the clinical efficacy rate,disease recurrence rate,changes of FENO,sputum eosinophil(EOS),serum immunoglobulin E(IgE)and interleukin-5(IL-5)before and after the treatment.Results After three months of treatment,the efficacy rate of the treatment group was significantly higher than that of the control group(92.45%vs 75.47%,P<0.05);after drug withdrawal and dosage reduction,the total recurrence rate of disease in the treatment group within half year was significantly lower than that in the control group(26.41%vs 47.16%;P<0.05);the treatment group had more significant decrease than the control group in the levels of FENO,EOS,IgE and IL-5(P<0.05).Conclusion In the treatment of patients with CARAS,the nasal inflammation should be controlled;additionally,the combination of budesonide nasal spray and conventional therapy of asthma can significantly reduce the levels of inflammatory cytokines and recurrence rate and improve the disease prognosis,which deserves clinical promotion and reference.
作者
吴明亚
李光清
吴昭萍
李东
孙建
Wu Mingya;Li Guangqing;Wu Zhaoping;Li Dong;Sun Jian(Department of Respiratory Medicine,Air Force Hospital of Western Theater Command of PLA,Chengdu,Sichuan,610021,China;Department of Respiratory Medicine,the First Affiliated Hospital of Chengdu Medical College,Chengdu,Sichuan,610500,China)
出处
《西南国防医药》
CAS
2020年第3期211-214,共4页
Medical Journal of National Defending Forces in Southwest China
基金
成都医学院第一附属医院专项科学研究基金科研计划(CYFY2018GLPHX04)。
